title: Treatment of solid tumors following allogeneic bone marrow transplantation.
abstract: Second solid tumors are well known late complications after bone marrow transplantation. Treatment strategies are ill defined. We retrospectively evaluated treatment and outcome in a single institution. From August 1974 to July 1996, six solid tumors were observed in five of 387 patients 2 to 13 years after BMT, corresponding to a probability of developing a second solid tumor of 9% (1-17%, 95 CI) at 15 years: these comprised endometrial carcinoma, carcinoma of the thyroid gland, cervical carcinoma, sarcoma of the small intestine, osteosarcoma of the tibia and ovarian carcinoma. All five patients were treated as intensively as they would be without a history of BMT. At last follow-up four of the five patients were alive and without signs of tumor. We postulate that second solid tumors after BMT should be treated as de novo tumors. Early detection based on consequent clinical follow-up of the transplant patients might explain the relatively good outcome.
authors.affiliation: Divisions of Hematology, Department of Internal Medicine, Kantonsspital Basel, Basel, Switzerland.
authors.forename: G
authors.initials: G
authors.lastname: Favre-Schmuziger
authors.forename: S
authors.initials: S
authors.lastname: Hofer
authors.forename: J
authors.initials: J
authors.lastname: Passweg
authors.forename: A
authors.initials: A
authors.lastname: Tichelli
authors.forename: T
authors.initials: T
authors.lastname: Hoffmann
authors.forename: B
authors.initials: B
authors.lastname: Speck
authors.forename: R
authors.initials: R
authors.lastname: Herrmann
authors.forename: A
authors.initials: A
authors.lastname: Gratwohl
mesh_terms: D000230:Adenocarcinoma / Q000209:etiology / Q000628:therapy; D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002278:Carcinoma in Situ / Q000209:etiology / Q000628:therapy; D002291:Carcinoma, Papillary / Q000209:etiology / Q000628:therapy; D002648:Child; D015331:Cohort Studies; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007890:Leiomyosarcoma / Q000209:etiology / Q000628:therapy; D008297:Male; D016609:Neoplasms, Second Primary / Q000209:etiology / Q000628:therapy*; D012516:Osteosarcoma / Q000209:etiology / Q000628:therapy; D012189:Retrospective Studies; D013534:Survival; D014184:Transplantation, Homologous; D016896:Treatment Outcome